RxDoctor Payments Data

Timothy Dunn, MD

Neurology · Westampton, NJNPI 1669523445

Payments from drug & device makers

$39,108in general payments, 2019–2025

Across 1,467 payments — averaging $26.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • EMD Serono, Inc.$3K
  • Teva Pharmaceuticals USA, Inc.$3K
  • Eisai Inc.$2K
  • Biogen$2K
  • UCB, Inc.$2K
  • plus $18K from 54 others

What the payments were for

  • Consulting fees$2,1686%
  • Speaking & faculty fees$4,45411%
  • Travel & lodging$1,3714%
  • Food & beverage$30,65978%
  • Education$4561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)196$7,569
EMD Serono, Inc.196$3,213
Teva Pharmaceuticals USA, Inc.118$3,123
Eisai Inc.55$2,324
Biogen86$2,252
UCB, Inc.90$2,213
E.r. Squibb & Sons, L.L.C.26$2,023
Bristol Myers Squibb75$1,487
Lilly USA, LLC67$1,125
Amgen(2 entities)37$1,107
SK Life Science, Inc.23$925
AstraZeneca24$853
Supernus Pharmaceuticals, Inc.24$851
Neurocrine Biosciences, Inc.30$739
Lundbeck LLC27$717
Axsome Therapeutics, Inc.13$694
Pfizer28$602
Jazz Pharmaceuticals Inc.18$489
Argenx US, Inc.15$461
Biohaven Pharmaceuticals, Inc.17$451
Harmony Biosciences LLC16$386
Novartis26$381
Avanir Pharmaceuticals, Inc.10$300
Ironshore Pharmaceuticals Inc.13$285
Scilex Pharmaceuticals Inc.16$250
W. L. Gore & Associates, Inc.15$234
Otsuka America Pharmaceutical, Inc.10$231
Kyowa Kirin, Inc.9$227
Acorda Therapeutics, Inc9$214
Sanofi8$211
Aucta Pharmaceuticals, Inc.12$164
Neurelis, Inc.11$159
TG Therapeutics, Inc.3$158
Sunovion Pharmaceuticals Inc.9$156
Biohaven Pharmaceutical Holding Company Ltd.8$149
Avion Pharmaceuticals7$136
Medtronic1$126
Impel Pharmaceuticals Inc.2$118
Amneal Pharmaceuticals LLC7$116
Sumitomo Pharma America, Inc.6$116
Tris Pharma Inc7$107
Corium, LLC7$100
Genentech USA, Inc.5$96
Aquestive Therapeutics, Inc.5$94
Takeda Pharmaceuticals U.S.A., Inc.7$93
Otsuka Pharmaceutical Development & Commercialization, Inc.1$90
Akcea Therapeutics, Inc.4$85
Aprecia Pharmaceuticals, LLC5$83
Banner Life Sciences, LLC6$80
Grifols USA, LLC4$73
Adamas Pharmaceuticals, Inc.5$71
Avadel CNS Pharmaceuticals, LLC4$69
Noven Therapeutics, LLC4$67
Vanda Pharmaceuticals Inc.4$66
MDD US Operations, LLC3$66
Johnson & Johnson4$60
Boston Scientific2$50
Adlon Therapeutics L.p.3$43
Zyla Life Sciences, Inc.3$37
Insightec,inc1$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,108 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$83,860
Medicare patients
420
Services billed
652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate13$130,258
Aimovig AutoinjectorErenumab-Aooe102$90,636
CopaxoneGlatiramer Acetate14$74,000
AustedoDeutetrabenazine12$70,169
UbrelvyUbrogepant47$64,690
AmpyraDalfampridine11$40,304
QuliptaAtogepant30$34,958
BriviactBrivaracetam23$33,199
NourianzIstradefylline13$24,076
Dimethyl Fumarate23$20,078
Lacosamide91$17,275
Memantine Hcl461$15,574
Levetiracetam272$12,321
Divalproex Sodium57$9,646
Gabapentin417$8,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone, Austedo$3,123$144,16926 claims
BiogenVumerity$2,252$130,25813 claims
AbbVieUbrelvy, Qulipta$7,569$99,64977 claims
Acorda Therapeutics, IncAmpyra$214$40,30411 claims
UCB, Inc.Briviact$2,213$33,19923 claims
Kyowa Kirin, Inc.Nourianz$227$24,07613 claims
PfizerDilantin$602$6,83521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 521 neurology providers in New Jersey.

Other neurology in Westampton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →